Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate.

Chen, Luohai; Gnanasegaran, Gopinath; Mandair, Dalvinder; Toumpanakis, Christos; Caplin, Martyn; Navalkissoor, Shaunak

Chen, Luohai; Gnanasegaran, Gopinath; Mandair, Dalvinder; Toumpanakis, Christos; Caplin, Martyn; Navalkissoor, Shaunak.

Afiliação

Chen L; Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK.
Gnanasegaran G; Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Mandair D; Institute for Liver and Digestive Disease, Royal Free Hospital, University College London, London, UK.
Toumpanakis C; Department of Nuclear Medicine, Royal Free London NHS Foundation, London, UK.
Caplin M; Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK.
Navalkissoor S; Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation, London, UK.

Endocr Relat Cancer ; 29(2): 111-120, 2022 01 20.

Article em En | MEDLINE | ID: mdl-34932018

Assuntos

Tumores Neuroendócrinos; Compostos Organometálicos; Humanos; Tumores Neuroendócrinos/tratamento farmacológico; Tumores Neuroendócrinos/radioterapia; Octreotida/uso terapêutico; Compostos Organometálicos/uso terapêutico; Tomografia por Emissão de Pósitrons; Prognóstico; Intervalo Livre de Progressão; Cintilografia; Estudos Retrospectivos

Palavras-chave

177Lu-Dotatate; PRRT; biomarker; neuroendocrine tumours; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Tumores Neuroendócrinos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google